Medifast, Inc.

The stock is still in a longer-term repair phase after a sharp reset from its 52-week high of 15.46, but it has stabilized well above the 52-week low of 9.22. Price remains below the 200-day average of 11.62, so the broader trend is still rebuilding rather than fully confirmed.

Street sentiment is cautious but constructive: consensus sits at Hold with a $12 target, modestly above the last close. The recent pattern is mostly target cuts and neutral calls, with Stephens lowering its target to $12 in February 2026, suggesting expectations have reset but not turned bearish.

The earnings profile is mixed but improving at the margin. Medifast has beaten in 5 of the last 7 quarters, including a 63.5% EPS beat in the most recent reported quarter, while next-year EPS estimates still point to a loss of -0.60 after -1.85 for 2026. Shareholders should watch whether revenue stabilization follows the recent beat pattern.

Insider activity leans positive, but most of the recent prints are award-related and not true trading signals. The only discretionary buying was two purchases by Director Scott Schlackman in May 2026 totaling 5,000 shares, while the larger May grants to several directors look like compensation awards.

Profitability remains under pressure, with a -7.21% operating margin and -5.79% net margin, but gross margin is still a strong 70.1%. Cash generation and liquidity are the offset: 2025 free cash flow was $12.48 million and the balance sheet held $167.27 million in cash against $16.79 million of debt.

Medifast looks like a smaller, higher-risk turnaround versus broader personal services peers, with a low beta of 0.659 and a business model tied to weight-loss coaching and product sales. The valuation screen is still depressed, with a negative P/E and a market cap of about $119 million, leaving the setup more recovery-driven than premium.